{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:27:47Z","timestamp":1790699267873,"version":"4.1.0"},"reference-count":93,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Effusions or body cavity fluids are amongst the most commonly submitted samples to the cytology laboratory. Knowledge of proper collection, storage, preservation and processing techniques is essential to ensure proper handling and successful analysis of the sample. This article describes how the effusions should be collected and proper conditions for submission. The different processing techniques to extract the cellular material and prepare slides satisfactory for microscopic evaluation are described such as direct smears, cytospins, liquid based preparations and cell blocks. The article further elaborates on handling the specimens for additional ancillary testing such as immunostaining and molecular tests, including predictive ones, as well as future research approaches.<\/jats:p>","DOI":"10.1515\/pp-2016-0001","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T15:15:08Z","timestamp":1460560508000},"page":"45-56","source":"Crossref","is-referenced-by-count":39,"title":["Pre-analytical issues in effusion cytology"],"prefix":"10.1515","volume":"1","author":[{"given":"Claire W.","family":"Michael","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"2025120909190350495_j_pp-2016-0001_ref_001_w2aab3b7b5b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"1. Gill GW. Cytopreparation: principles & practice, Rosenthal D, editor. London: Springer, 2013.","DOI":"10.1007\/978-1-4614-4933-1"},{"key":"2025120909190350495_j_pp-2016-0001_ref_002_w2aab3b7b5b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"2. Roffe BD, Wagner FH, Derewicz HJ, Gill GW. Heparinized bottles for the collection of body cavity fluids in cytopathology. Am J Hosp Pharm 1979;36:211\u201314.","DOI":"10.1093\/ajhp\/36.2.211"},{"key":"2025120909190350495_j_pp-2016-0001_ref_003_w2aab3b7b5b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"3. Naylor B. Pleural, peritoneal and pericardial fluids. In: Boibbo M, editor. Comprehensive cytopathology. Philadelphia: WB Saunders, 2008:515\u201377.","DOI":"10.1016\/B978-141604208-2.10019-3"},{"key":"2025120909190350495_j_pp-2016-0001_ref_004_w2aab3b7b5b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"4. Bou-Khalil PK, Jamaleddine GW, Debek AH, El-Khatib MF. Use of heparinized versus non-heparinized syringes for measurements of the pleural fluid pH. Respiration 2007;74:659\u201362.","DOI":"10.1159\/000106844"},{"key":"2025120909190350495_j_pp-2016-0001_ref_005_w2aab3b7b5b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"5. Rooper LM, Ali SZ, Olson MTA Minimum volume of more than 60 mL is necessary for adequate cytologic diagnosis of malignant pericardial effusions. Am J Clin Path 2016;145:101\u20136.","DOI":"10.1093\/ajcp\/aqv021"},{"key":"2025120909190350495_j_pp-2016-0001_ref_006_w2aab3b7b5b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"6. Rooper LM, Ali SZ, Olson MT. A minimum fluid volume of 75 mL is needed to ensure adequacy in a pleural effusion: a retrospective analysis of 2540 cases. Cancer Cytopathol 2014;122:657\u201365.","DOI":"10.1002\/cncy.21452"},{"key":"2025120909190350495_j_pp-2016-0001_ref_007_w2aab3b7b5b1b6b1ab2b1b7Aa","unstructured":"7. Guzman J, Arbogast S, Bross KJ, Finke R, Costabel U. Effect of storage time of pleural effusions on immunocytochemical cell surface analysis of tumor cells. Anal Quant Cytol Histol 1992;14:203\u20139."},{"key":"2025120909190350495_j_pp-2016-0001_ref_008_w2aab3b7b5b1b6b1ab2b1b8Aa","unstructured":"8. Guzman J, Arbogast S, Bross KJ, Finke R, Costabel U. Effect of storage time on the analysis of lymphocyte subpopulations in pleural effusions. Acta Cytol 1993;37:267\u201371."},{"key":"2025120909190350495_j_pp-2016-0001_ref_009_w2aab3b7b5b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"9. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, et al. Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol 2007;35:6\u201311.","DOI":"10.1002\/dc.20587"},{"key":"2025120909190350495_j_pp-2016-0001_ref_010_w2aab3b7b5b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"10. Antonangelo L, Vargas FS, Almeida LP, Acencio MM, Gomes FD, Sales RK, et al. Influence of storage time and temperature on pleural fluid adenosine deaminase determination. Respirology 2006;11:488\u201392.","DOI":"10.1111\/j.1440-1843.2006.00866.x"},{"key":"2025120909190350495_j_pp-2016-0001_ref_011_w2aab3b7b5b1b6b1ab2b1c11Aa","unstructured":"11. Ng WF, Choi FB, Cheung LL, Wu C, Leung CF, Ng CS. Rehydration of air-dried smears with normal saline. Application in fluid cytology. Acta Cytol 1994;38:56\u201364."},{"key":"2025120909190350495_j_pp-2016-0001_ref_012_w2aab3b7b5b1b6b1ab2b1c12Aa","unstructured":"12. Starr RL, Sherman ME. The value of multiple preparations in the diagnosis of malignant pleural effusions. A cost-benefit analysis. Acta Cytol 1991;35:533\u20137."},{"key":"2025120909190350495_j_pp-2016-0001_ref_013_w2aab3b7b5b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"13. Venrick MG, Sidawy MK. Cytologic evaluation of serous effusions. Processing techniques and optimal number of smears for routine preparation. Am J Clin Path 1993;99:182\u20136.","DOI":"10.1093\/ajcp\/99.2.182"},{"key":"2025120909190350495_j_pp-2016-0001_ref_014_w2aab3b7b5b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"14. Michael CW, Bedrossian CC. The implementation of liquid-based cytology for lung and pleural-based diseases. Acta Cytol 2014;58:563\u201373.","DOI":"10.1159\/000369198"},{"key":"2025120909190350495_j_pp-2016-0001_ref_015_w2aab3b7b5b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"15. Curry JL, Wojcik EM. Malignant pericardial effusion with metastatic squamous-cell carcinoma: discordance between ThinPrep and cell-block cytopreparation. Diagn Cytopathol 2003;29:270.","DOI":"10.1002\/dc.10327"},{"key":"2025120909190350495_j_pp-2016-0001_ref_016_w2aab3b7b5b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"16. Collins GR, Thomas J, Joshi N, Zhang S. The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. Cancer Cytopathol 2012;120:134\u201341.","DOI":"10.1002\/cncy.20181"},{"key":"2025120909190350495_j_pp-2016-0001_ref_017_w2aab3b7b5b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"17. Gauchotte G, Vignaud JM, Menard O, Wissler MP, Martinet Y, Siat J, et al. A combination of smears and cell block preparations provides high diagnostic accuracy for endobronchial ultrasound-guided transbronchial needle aspiration. Virchows Arch 2012;461:505\u201312.","DOI":"10.1007\/s00428-012-1296-x"},{"key":"2025120909190350495_j_pp-2016-0001_ref_018_w2aab3b7b5b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"18. Wallace WA, Monaghan HM, Salter DM, Gibbons MA, Skwarski KM. Endobronchial ultrasound-guided fine-needle aspiration and liquid-based thin-layer cytology. J Clin Pathol 2007;60:388\u201391.","DOI":"10.1136\/jcp.2006.038901"},{"key":"2025120909190350495_j_pp-2016-0001_ref_019_w2aab3b7b5b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"19. Arabi H, Yousef N, Han L, Bandyopadhyay S, Feng J, Al-Abbadi M. Accuracy and added value of triage beyond segregating potentially neoplastic effusions in immediate wet preparation. Acta Cytol 2009;53:71\u20136.","DOI":"10.1159\/000325086"},{"key":"2025120909190350495_j_pp-2016-0001_ref_020_w2aab3b7b5b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"20. Erkilic S, Kocer NE. Diagnostic accuracy of toluidine blue-stained wet films in effusion cytology. Acta Cytol 2006;50:407\u20139.","DOI":"10.1159\/000325982"},{"key":"2025120909190350495_j_pp-2016-0001_ref_021_w2aab3b7b5b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"21. Filie AC, Copel C, Wilder AM, Abati A. Individual specimen triage of effusion samples: an improvement in the standard of practice, or a waste of resources? Diagn Cytopathol 2000;22:7\u201310.","DOI":"10.1002\/(SICI)1097-0339(200001)22:1<7::AID-DC3>3.0.CO;2-U"},{"key":"2025120909190350495_j_pp-2016-0001_ref_022_w2aab3b7b5b1b6b1ab2b1c22Aa","unstructured":"22. Varsegi GM, Shidham V. Cell block preparation [using Histogel] from cytology specimen with predominance of individually scattered cells. J Vis Ex 2009;29:e1316. http:\/\/www.jove.com\/index\/Details.stp?ID=1316. last opened 3\/8\/2016."},{"key":"2025120909190350495_j_pp-2016-0001_ref_023_w2aab3b7b5b1b6b1ab2b1c23Aa","unstructured":"23. Scientific TSR-A. Histogel: instructions for use. 92957066 R11\/08. 2012."},{"key":"2025120909190350495_j_pp-2016-0001_ref_024_w2aab3b7b5b1b6b1ab2b1c24Aa","unstructured":"24. Corporation TE. Shandon Cytoblock cell block preparation system. 2012."},{"key":"2025120909190350495_j_pp-2016-0001_ref_025_w2aab3b7b5b1b6b1ab2b1c25Aa","unstructured":"25. Hologic I. 2010."},{"key":"2025120909190350495_j_pp-2016-0001_ref_026_w2aab3b7b5b1b6b1ab2b1c26Aa","unstructured":"26. Jonasson JG, Ducatman BS, Wang HH. The cell block for body cavity fluids: do the results justify the cost? Mod Pathol 1990;3:667\u201370."},{"key":"2025120909190350495_j_pp-2016-0001_ref_027_w2aab3b7b5b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"27. Nathan NA, Narayan E, Smith MM, Horn MJ. Cell block cytology. Improved preparation and its efficacy in diagnostic cytology. Am J Clin Path 2000;114:599\u2013606.","DOI":"10.1309\/G035-P2MM-D1TM-T5QE"},{"key":"2025120909190350495_j_pp-2016-0001_ref_028_w2aab3b7b5b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"28. Kulkarni MB, Desai SB, Ajit D, Chinoy RF. Utility of the thromboplastin-plasma cell-block technique for fine-needle aspiration and serous effusions. Diagn Cytopathol 2009;37:86\u201390.","DOI":"10.1002\/dc.20963"},{"key":"2025120909190350495_j_pp-2016-0001_ref_029_w2aab3b7b5b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"29. Ueda J, Iwata T, Ono M, Takahashi M. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion. Diagn Cytopathol 2006;34:6\u201310.","DOI":"10.1002\/dc.20391"},{"key":"2025120909190350495_j_pp-2016-0001_ref_030_w2aab3b7b5b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"30. Fetsch PA, Simsir A, Brosky K, Abati A. Comparison of three commonly used cytologic preparations in effusion immunocytochemistry. Diagn Cytopathol 2002;26:61\u20136.","DOI":"10.1002\/dc.10039"},{"key":"2025120909190350495_j_pp-2016-0001_ref_031_w2aab3b7b5b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"31. Shidham VB, Lindholm PF, Kajdacsy-Balla A, Chang CC, Komorowski R. Methods of cytologic smear preparation and fixation. Effect on the immunoreactivity of commonly used anticytokeratin antibody AE1\/AE3. Acta Cytol 2000;44:1015\u201322.","DOI":"10.1159\/000328590"},{"key":"2025120909190350495_j_pp-2016-0001_ref_032_w2aab3b7b5b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"32. Shidham VB, Chang CC, Rao RN, Komorowski R, Chivukula M. Immunostaining of cytology smears: a comparative study to identify the most suitable method of smear preparation and fixation with reference to commonly used immunomarkers. Diagn Cytopathol 2003;29:217\u201321.","DOI":"10.1002\/dc.10364"},{"key":"2025120909190350495_j_pp-2016-0001_ref_033_w2aab3b7b5b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"33. Knoepp SM, Placido J, Fields KL, Thomas D, Roh MH. The application of immunocytochemistry to direct smears in the diagnosis of effusions. Diagn Cytopathol 2013;41:425\u201330.","DOI":"10.1002\/dc.22852"},{"key":"2025120909190350495_j_pp-2016-0001_ref_034_w2aab3b7b5b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"34. Roh MH, Schmidt L, Placido J, Farmen S, Fields KL, Courey AJ, et al. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma. Diagn Cytopathol 2012;40:949\u201355.","DOI":"10.1002\/dc.21680"},{"key":"2025120909190350495_j_pp-2016-0001_ref_035_w2aab3b7b5b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"35. Gong Y, Sun X, Michael CW, Attal S, Williamson BA, Bedrossian CW. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol 2003;28:1\u20135.","DOI":"10.1002\/dc.10219"},{"key":"2025120909190350495_j_pp-2016-0001_ref_036_w2aab3b7b5b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"36. Jing X, Michael CW, Theoharis CG. The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies. Diagn Cytopathol 2013;41:126\u201330.","DOI":"10.1002\/dc.21791"},{"key":"2025120909190350495_j_pp-2016-0001_ref_037_w2aab3b7b5b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"37. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008;63:35\u201341.","DOI":"10.1136\/thx.2007.077958"},{"key":"2025120909190350495_j_pp-2016-0001_ref_038_w2aab3b7b5b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"38. Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol 2015;59:2\u201316.","DOI":"10.1159\/000377697"},{"key":"2025120909190350495_j_pp-2016-0001_ref_039_w2aab3b7b5b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"39. Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer 2013;133:645\u201352.","DOI":"10.1002\/ijc.28054"},{"key":"2025120909190350495_j_pp-2016-0001_ref_040_w2aab3b7b5b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"40. Vaksman O, Trope C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014;35:2113\u201320.","DOI":"10.1093\/carcin\/bgu130"},{"key":"2025120909190350495_j_pp-2016-0001_ref_041_w2aab3b7b5b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"41. Xie L, Chen X, Wang L, Qian X, Wang T, Wei J, et al. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC cancer 2010;10:591.","DOI":"10.1186\/1471-2407-10-591"},{"key":"2025120909190350495_j_pp-2016-0001_ref_042_w2aab3b7b5b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"42. Vettukattil R, Hetland TE, Florenes VA, Kaern J, Davidson B, Bathen TF. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. Hum Pathol 2013;44:1859\u201366.","DOI":"10.1016\/j.humpath.2013.02.009"},{"key":"2025120909190350495_j_pp-2016-0001_ref_043_w2aab3b7b5b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"43. Salani R, Davidson B, Fiegl M, Marth C, Muller-Holzner E, Gastl G, et al. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res 2007;13:5805\u20139.","DOI":"10.1158\/1078-0432.CCR-07-0853"},{"key":"2025120909190350495_j_pp-2016-0001_ref_044_w2aab3b7b5b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"44. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, et al. Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer 2009;125:1921\u20135.","DOI":"10.1002\/ijc.24516"},{"key":"2025120909190350495_j_pp-2016-0001_ref_045_w2aab3b7b5b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"45. Rosolen DC, Kulikowski LD, Bottura G, Nascimento AM, Acencio M, Teixeira L, et al. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions. Lung Cancer 2013;80:284\u20138.","DOI":"10.1016\/j.lungcan.2013.02.001"},{"key":"2025120909190350495_j_pp-2016-0001_ref_046_w2aab3b7b5b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"46. Han J, Cao S, Zhang K, Zhao G, Xin Y, Dong Q, et al. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions. J Cardiothorac Surg 2012;7:121.","DOI":"10.1186\/1749-8090-7-121"},{"key":"2025120909190350495_j_pp-2016-0001_ref_047_w2aab3b7b5b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"47. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003;99:51\u20136.","DOI":"10.1002\/cncr.10923"},{"key":"2025120909190350495_j_pp-2016-0001_ref_048_w2aab3b7b5b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"48. Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, et al. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol 2013;121:415\u201322.","DOI":"10.1002\/cncy.21269"},{"key":"2025120909190350495_j_pp-2016-0001_ref_049_w2aab3b7b5b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"49. Shin HJ, Shin DM, Tarco E, Sneige N. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma. Cancer 2003;99:233\u20139.","DOI":"10.1002\/cncr.11398"},{"key":"2025120909190350495_j_pp-2016-0001_ref_050_w2aab3b7b5b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"50. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 2010;68:39\u201343.","DOI":"10.1016\/j.lungcan.2009.05.004"},{"key":"2025120909190350495_j_pp-2016-0001_ref_051_w2aab3b7b5b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"51. Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010;138:137\u201344.","DOI":"10.1378\/chest.09-1951"},{"key":"2025120909190350495_j_pp-2016-0001_ref_052_w2aab3b7b5b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"52. Schluter B, Gerhards R, Strumberg D, Voigtmann R. Combined detection of Her2\/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol 2010;136:1389\u2013400.","DOI":"10.1007\/s00432-010-0790-2"},{"key":"2025120909190350495_j_pp-2016-0001_ref_053_w2aab3b7b5b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"53. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;104:1372\u20136.","DOI":"10.1038\/bjc.2011.121"},{"key":"2025120909190350495_j_pp-2016-0001_ref_054_w2aab3b7b5b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"54. Arihiro K, Oda M, Ogawa K, Tominaga K, Kaneko Y, Shimizu T, et al. Discordant HER2 status between primary breast carcinoma and recurrent\/metastatic tumors using fluorescence in situ hybridization on cytological samples. Jp J Clin Oncol 2013;43:55\u201362.","DOI":"10.1093\/jjco\/hys187"},{"key":"2025120909190350495_j_pp-2016-0001_ref_055_w2aab3b7b5b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"55. Shabaik A, Lin G, Peterson M, Hasteh F, Tipps A, Datnow B, et al. Reliability of Her2\/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39:328\u201332.","DOI":"10.1002\/dc.21389"},{"key":"2025120909190350495_j_pp-2016-0001_ref_056_w2aab3b7b5b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"56. Li X, Wan L, Shen H, Geng J, Nie J, Wang G, et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol 2012;7:76\u201384.","DOI":"10.1097\/JTO.0b013e318232b98a"},{"key":"2025120909190350495_j_pp-2016-0001_ref_057_w2aab3b7b5b1b6b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"57. Davidson B, Goldberg I, Tell L, Vigdorchik S, Baekelandt M, Berner A, et al. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 2004;21:191\u20139.","DOI":"10.1023\/B:CLIN.0000037703.37275.35"},{"key":"2025120909190350495_j_pp-2016-0001_ref_058_w2aab3b7b5b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"58. Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, et al. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 2002;19:135\u201344.","DOI":"10.1023\/A:1014582911680"},{"key":"2025120909190350495_j_pp-2016-0001_ref_059_w2aab3b7b5b1b6b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"59. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005;103:1631\u201343.","DOI":"10.1002\/cncr.20946"},{"key":"2025120909190350495_j_pp-2016-0001_ref_060_w2aab3b7b5b1b6b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"60. Tsai TH, Wu SG, Chang YL, Wu CT, Tsai MF, Wei PF, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012;7:993\u20131000.","DOI":"10.1097\/JTO.0b013e31824cc46b"},{"key":"2025120909190350495_j_pp-2016-0001_ref_061_w2aab3b7b5b1b6b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"61. Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012;23:2914\u201319.","DOI":"10.1093\/annonc\/mds121"},{"key":"2025120909190350495_j_pp-2016-0001_ref_062_w2aab3b7b5b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"62. Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathol 2013;121:311\u201319.","DOI":"10.1002\/cncy.21260"},{"key":"2025120909190350495_j_pp-2016-0001_ref_063_w2aab3b7b5b1b6b1ab2b1c63Aa","unstructured":"63. Veldore VH, Patil S, Prabhudesai S, Satheesh CT, Shashidhara HP, Krishnamoorthy N, et al. Targeted therapy management in NSCLC patients using cytology: experience from a tertiary care cancer center. Mol Diagn Ther 2016 Jan 6. (Epub ahead of print) PMID 26740090."},{"key":"2025120909190350495_j_pp-2016-0001_ref_064_w2aab3b7b5b1b6b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"64. Yeo CD, Kim JW, Kim KH, Ha JH, Rhee CK, Kim SJ, et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer 2013;81:207\u201312.","DOI":"10.1016\/j.lungcan.2013.04.023"},{"key":"2025120909190350495_j_pp-2016-0001_ref_065_w2aab3b7b5b1b6b1ab2b1c65Aa","doi-asserted-by":"crossref","unstructured":"65. Liu X, Lu Y, Zhu G, Lei Y, Zheng L, Qin H, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol 2013;66:1065\u20139.","DOI":"10.1136\/jclinpath-2013-201728"},{"key":"2025120909190350495_j_pp-2016-0001_ref_066_w2aab3b7b5b1b6b1ab2b1c66Aa","doi-asserted-by":"crossref","unstructured":"66. Buttitta F, Felicioni L, Del Grammastro M, Filice G, Di Lorito A, Malatesta S, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 2013;19:691\u20138.","DOI":"10.1158\/1078-0432.CCR-12-1958"},{"key":"2025120909190350495_j_pp-2016-0001_ref_067_w2aab3b7b5b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"67. Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 2012;18:5682\u20139.","DOI":"10.1158\/1078-0432.CCR-11-2947"},{"key":"2025120909190350495_j_pp-2016-0001_ref_068_w2aab3b7b5b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"68. Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012;7:98\u2013104.","DOI":"10.1097\/JTO.0b013e3182370e30"},{"key":"2025120909190350495_j_pp-2016-0001_ref_069_w2aab3b7b5b1b6b1ab2b1c69Aa","doi-asserted-by":"crossref","unstructured":"69. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer 2015;88:208\u201314.","DOI":"10.1016\/j.lungcan.2015.02.018"},{"key":"2025120909190350495_j_pp-2016-0001_ref_070_w2aab3b7b5b1b6b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"70. Saito T, Kobayashi M, Harada R, Uemura Y, Taguchi H. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA. Cancer 2003;97:2504\u201311.","DOI":"10.1002\/cncr.11378"},{"key":"2025120909190350495_j_pp-2016-0001_ref_071_w2aab3b7b5b1b6b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"71. Fiegl M, Haun M, Massoner A, Krugmann J, Muller-Holzner E, Hack R, et al. Combination of cytology, fluorescence in situ hybridization for aneuploidy, and reverse-transcriptase polymerase chain reaction for human mammaglobin\/mammaglobin B expression improves diagnosis of malignant effusions. J Clin Oncol 2004;22:474\u201383.","DOI":"10.1200\/JCO.2004.06.063"},{"key":"2025120909190350495_j_pp-2016-0001_ref_072_w2aab3b7b5b1b6b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"72. Mohamed F, Vincent N, Cottier M, Peoc\u2019h M, Merrouche Y, Patouillard B, et al. Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression. Biomarkers 2010;15:315\u201324.","DOI":"10.3109\/13547501003658114"},{"key":"2025120909190350495_j_pp-2016-0001_ref_073_w2aab3b7b5b1b6b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"73. Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih Ie M, et al. Gene expression signatures differentiate ovarian\/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2011;15:535\u201344.","DOI":"10.1111\/j.1582-4934.2010.01019.x"},{"key":"2025120909190350495_j_pp-2016-0001_ref_074_w2aab3b7b5b1b6b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"74. Davidson B, Stavnes HT, Risberg B, Nesland JM, Wohlschlaeger J, Yang Y, et al. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Hum Pathol 2012;43:684\u201394.","DOI":"10.1016\/j.humpath.2011.06.015"},{"key":"2025120909190350495_j_pp-2016-0001_ref_075_w2aab3b7b5b1b6b1ab2b1c75Aa","doi-asserted-by":"crossref","unstructured":"75. Davidson B, Zhang Z, Kleinberg L, Li M, Florenes VA, Wang TL, et al. Gene expression signatures differentiate ovarian\/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006;12:5944\u201350.","DOI":"10.1158\/1078-0432.CCR-06-1059"},{"key":"2025120909190350495_j_pp-2016-0001_ref_076_w2aab3b7b5b1b6b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"76. Bock AJ, Nymoen DA, Brenne K, Kaern J, Davidson B. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. Hum Pathol 2012;43:669\u201374.","DOI":"10.1016\/j.humpath.2011.06.003"},{"key":"2025120909190350495_j_pp-2016-0001_ref_077_w2aab3b7b5b1b6b1ab2b1c77Aa","doi-asserted-by":"crossref","unstructured":"77. Brenne K, Nymoen DA, Hetland TE, Trope CG, Davidson B. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol 2012;43:496\u2013505.","DOI":"10.1016\/j.humpath.2011.05.023"},{"key":"2025120909190350495_j_pp-2016-0001_ref_078_w2aab3b7b5b1b6b1ab2b1c78Aa","doi-asserted-by":"crossref","unstructured":"78. Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Path 2012;137:240\u20137.","DOI":"10.1309\/AJCPGA95KVSAUDMF"},{"key":"2025120909190350495_j_pp-2016-0001_ref_079_w2aab3b7b5b1b6b1ab2b1c79Aa","doi-asserted-by":"crossref","unstructured":"79. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B. Rab25 is overexpressed in Mullerian serous carcinoma compared to malignant mesothelioma. Virchows Arch 2012;460:193\u2013202.","DOI":"10.1007\/s00428-011-1191-x"},{"key":"2025120909190350495_j_pp-2016-0001_ref_080_w2aab3b7b5b1b6b1ab2b1c80Aa","doi-asserted-by":"crossref","unstructured":"80. Stavnes HT, Nymoen DA, Langerod A, Holth A, Borresen Dale AL, Davidson B. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. Virchows Arch 2013;462:163\u201373.","DOI":"10.1007\/s00428-012-1347-3"},{"key":"2025120909190350495_j_pp-2016-0001_ref_081_w2aab3b7b5b1b6b1ab2b1c81Aa","doi-asserted-by":"crossref","unstructured":"81. Yuan Y, Nymoen DA, Dong HP, Bjorang O, Shih Ie M, Low PS, et al. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol 2009;40:1453\u201360.","DOI":"10.1016\/j.humpath.2009.02.013"},{"key":"2025120909190350495_j_pp-2016-0001_ref_082_w2aab3b7b5b1b6b1ab2b1c82Aa","doi-asserted-by":"crossref","unstructured":"82. Yuan Y, Nymoen DA, Stavnes HT, Rosnes AK, Bjorang O, Wu C, et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 2009;33:1673\u201382.","DOI":"10.1097\/PAS.0b013e3181b6bde3"},{"key":"2025120909190350495_j_pp-2016-0001_ref_083_w2aab3b7b5b1b6b1ab2b1c83Aa","doi-asserted-by":"crossref","unstructured":"83. Hofmann M, Ruschenburg I. mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Cancer 2002;96:187\u201393.","DOI":"10.1002\/cncr.10622"},{"key":"2025120909190350495_j_pp-2016-0001_ref_084_w2aab3b7b5b1b6b1ab2b1c84Aa","doi-asserted-by":"crossref","unstructured":"84. Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci 2012;103:510\u201314.","DOI":"10.1111\/j.1349-7006.2011.02180.x"},{"key":"2025120909190350495_j_pp-2016-0001_ref_085_w2aab3b7b5b1b6b1ab2b1c85Aa","doi-asserted-by":"crossref","unstructured":"85. Hiraki M, Kitajima Y, Sato S, Nakamura J, Hashiguchi K, Noshiro H, et al. Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer. World J Gastroenterol 2010;16:330\u20138.","DOI":"10.3748\/wjg.v16.i3.330"},{"key":"2025120909190350495_j_pp-2016-0001_ref_086_w2aab3b7b5b1b6b1ab2b1c86Aa","doi-asserted-by":"crossref","unstructured":"86. Katayama H, Hiraki A, Aoe K, Fujiwara K, Matsuo K, Maeda T, et al. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 2007;120:2191\u20135.","DOI":"10.1002\/ijc.22576"},{"key":"2025120909190350495_j_pp-2016-0001_ref_087_w2aab3b7b5b1b6b1ab2b1c87Aa","doi-asserted-by":"crossref","unstructured":"87. Yang TM, Leu SW, Li JM, Hung MS, Lin CH, Lin YC, et al. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. J Cancer Res Clin Oncol 2009;135:919\u201324.","DOI":"10.1007\/s00432-008-0527-7"},{"key":"2025120909190350495_j_pp-2016-0001_ref_088_w2aab3b7b5b1b6b1ab2b1c88Aa","doi-asserted-by":"crossref","unstructured":"88. Benlloch S, Galbis-Caravajal JM, Martin C, Sanchez-Paya J, Rodriguez-Paniagua JM, Romero S, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006;107:1859\u201365.","DOI":"10.1002\/cncr.22190"},{"key":"2025120909190350495_j_pp-2016-0001_ref_089_w2aab3b7b5b1b6b1ab2b1c89Aa","doi-asserted-by":"crossref","unstructured":"89. Davidson B, Espina V, Steinberg SM, Florenes VA, Liotta LA, Kristensen GB, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res 2006;12:791\u20139.","DOI":"10.1158\/1078-0432.CCR-05-2516"},{"key":"2025120909190350495_j_pp-2016-0001_ref_090_w2aab3b7b5b1b6b1ab2b1c90Aa","doi-asserted-by":"crossref","unstructured":"90. Hsieh WY, Chen MW, Ho HT, You TM, Lu YT. Identification of differentially expressed proteins in human malignant pleural effusions. Eur Respir J 2006;28:1178\u201385.","DOI":"10.1183\/09031936.06.00135405"},{"key":"2025120909190350495_j_pp-2016-0001_ref_091_w2aab3b7b5b1b6b1ab2b1c91Aa","doi-asserted-by":"crossref","unstructured":"91. Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, et al. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer 2012;118:1543\u201353.","DOI":"10.1002\/cncr.26449"},{"key":"2025120909190350495_j_pp-2016-0001_ref_092_w2aab3b7b5b1b6b1ab2b1c92Aa","doi-asserted-by":"crossref","unstructured":"92. Tyan YC, Wu HY, Lai WW, Su WC, Liao PC. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J. Proteome Res 2005;4:1274\u201386.","DOI":"10.1021\/pr049746c"},{"key":"2025120909190350495_j_pp-2016-0001_ref_093_w2aab3b7b5b1b6b1ab2b1c93Aa","doi-asserted-by":"crossref","unstructured":"93. Yu CJ, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, et al. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res 2011;10:4671\u201382.","DOI":"10.1021\/pr2004743"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/1\/article-p45.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0001\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0001\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:36:56Z","timestamp":1765273016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0001\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,4,12]]},"published-print":{"date-parts":[[2016,3,1]]}},"alternative-id":["10.1515\/pp-2016-0001"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0001","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}